Scholarlink

Background <p>Thrombosis and embolism of cerebral arteries cause reduced blood flow and oxygen supply to the brain, resulting in neuronal damage and astrocyte activation, which leads to the release of glial fibrillary acidic protein (GFAP) into cerebrospinal fluid and blood. In this single-center case–control study we evaluated serum glial fibrillary acidic protein (GFAP) levels in patients with acute ischemic stroke and matched healthy controls and assessed associations with stroke severity and 3-month functional outcome.</p> Results <p>Mean GFAP serum level was significantly higher in cases (0.206 ± 0.097&#xa0;ng/mL) than controls (0.068 ± 0.058&#xa0;ng/mL, <i>p</i> &lt; 0.001). GFAP correlated positively with NIHSS on day 1 (r = 0.443, p = 0.027) and day 7 (r = 0.654, <i>p</i> &lt; 0.001) and with mRS at 3&#xa0;months (r = 0.632, p = 0.001). ROC analysis for discriminating acute ischemic stroke from healthy controls gave AUC 0.886 (95% CI 0.790–0.982); at a cutoff of 0.15&#xa0;ng/mL sensitivity was 76.0% (95% CI 54.9–90.6) and specificity 88.0% (95% CI 68.8–97.5). Post-hoc power for the observed case–control difference in means was &gt; 99% (Cohen’s d = 1.73).</p> Conclusion <p>Serum GFAP levels are significantly elevated in acute ischemic stroke and correlate with stroke severity and functional outcome, providing preliminary evidence supporting further investigation of GFAP as a potential prognostic biomarker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Glial fibrillary acidic protein: a potential blood biomarker for acute ischemic stroke

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Youssef Taha,
  • Rasha Soliman,
  • Ahmed Abd Elaziz,
  • Aya Ahmed,
  • Noha Abd ElMonem

摘要

Background

Thrombosis and embolism of cerebral arteries cause reduced blood flow and oxygen supply to the brain, resulting in neuronal damage and astrocyte activation, which leads to the release of glial fibrillary acidic protein (GFAP) into cerebrospinal fluid and blood. In this single-center case–control study we evaluated serum glial fibrillary acidic protein (GFAP) levels in patients with acute ischemic stroke and matched healthy controls and assessed associations with stroke severity and 3-month functional outcome.

Results

Mean GFAP serum level was significantly higher in cases (0.206 ± 0.097 ng/mL) than controls (0.068 ± 0.058 ng/mL, p < 0.001). GFAP correlated positively with NIHSS on day 1 (r = 0.443, p = 0.027) and day 7 (r = 0.654, p < 0.001) and with mRS at 3 months (r = 0.632, p = 0.001). ROC analysis for discriminating acute ischemic stroke from healthy controls gave AUC 0.886 (95% CI 0.790–0.982); at a cutoff of 0.15 ng/mL sensitivity was 76.0% (95% CI 54.9–90.6) and specificity 88.0% (95% CI 68.8–97.5). Post-hoc power for the observed case–control difference in means was > 99% (Cohen’s d = 1.73).

Conclusion

Serum GFAP levels are significantly elevated in acute ischemic stroke and correlate with stroke severity and functional outcome, providing preliminary evidence supporting further investigation of GFAP as a potential prognostic biomarker.